Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects
Verified date | September 2015 |
Source | Uman Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Lung cancer is one of the most prevalent and lethal neoplasias in the world. Currently used
chemotherapy regimens have been disappointing in improving overall survival. Decitabine is a
S-phase pyrimidine analog that induces DNA hypomethylation. This drug is currently used to
treat Myelodysplastic Syndrome ( MDS) and has been studied for the treatment of leukemia.
Genistein, is a soy extracted non-toxic isoflavone and phytoestrogen, which has been shown
to inhibit activity of cell signaling pathways, such as those driven by tyrosine kinases.
Results from in vitro experiments unambiguously demonstrated that the combination of these
two compounds induces a synergistic reduction of the multiplication of lung, colon, breast
and leukemic cancer cells. Consequently, clinical evaluation of this drug combination is
warranted in Non Small Cell Lung Cancer ( NSCLC), and it is hypothezised that this new
regimen will safely improve overall tumor response rate and cancer progression free
survival.
The proposed trial is a two part study: The phase I part is an open-label, dose-escalation
evaluation in subjects with advanced solid tumors who have failed standard therapies and for
whom no curative therapeutic option exists.
A cohort of three subjects will be treated per dose level. One cycle is 28 days. Five
different, increasing dose levels ranging from 60 mg/m2 to 500 mg/m2 of IV decitabine
combined with a fixed oral dose of 150 mg BID of genistein will be tested. The Maximum
Tolerated Dose (MTD) will be determined based on the occurrence of Dose Limiting Toxicities
(DLTs).
In the phase IIa part of the study, only Stage IIIb and IV advanced NSCLC patients will be
treated at the recommended decitabine MTD dose combined with genistein. Safety and
preliminary efficacy will be assessed. It is expected that a maximum sample of 46 patients
will be enrolled in this trial.
Status | Completed |
Enrollment | 20 |
Est. completion date | September 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Written Informed Consent. - Males or females. - 18-75 years. - Histologically or cytologically confirmed non-estrogen dependent advanced solid malignancy who has failed standard therapies and/or for which no curative therapeutic option exists (phase I) or ; - Histologically or cytologically confirmed NSCLC of stage IIIb or IV (phase IIa) that has failed or is ineligible to standard therapies. - One or more tumor lesions measurable by RECIST criteria - Life expectancy of at least 3 months. - ECOG performance of 2 or less. Exclusion Criteria: - Prior decitabine or genistein therapy. - Received cytotoxic agent, hormonal therapy, radiation therapy, or other targeted cancer therapies or investigational agent within 4 weeks prior to study entry. - Patients with confirmed estrogen receptor-positive cancers, or patients with a primary breast or endometrial cancer for which phenotyping analysis has not been performed. - Presence of uncontrolled brain metastases or leptomeningeal disease. - Uncontrolled cardiovascular disorders, including symptomatic heart failure, unstable angina and cardiac arrhythmias. - Inadequate baseline organ function as shown by following laboratory values : - Hemoglobin < 90 g/L - Absolute neutrophil count < 1,500 /microliter - Platelet count < 100,000 /microliter - Total bilirubin > 1.5 ULN - AST and ALT > 2.5 ULN - Creatinine clearance < 60 ml/min - To be dependent of oxygen treatment. - Active infections requiring antibiotics. - Pregnancy or breastfeeding. All women of child-bearing potential must have a negative pregnancy test prior to first receiving protocol therapy. - Known allergic reactions to soy derivatives or deoxycytidine derivatives. - Active alcohol or drug abuse. - Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect. - Other malignancies diagnosed within the last 5 years with the exception of Basal Cell Carcinoma of the skin. - Gastrointestinal disorders or abnormalities that may interfere with the absorption of genistein. - Patients unable to comply with the study protocol and follow-up schedule for any psychological, familial, sociological or geographical reason. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Hôpital Notre Dame du CHUM | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Uman Pharma | DSM Nutritional Products, Inc., INRS-Institut Armand Frappier , Université du Québec, MDEIE Ministry, Québec Government |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) | MTD determination will based on the incidence of reported adverse events (including dose-limiting toxicities) and abnormal laboratory test results. | 28 day treatment cycle for MTD assessment; 4-6 cycles to be administered | Yes |
Secondary | To determine the drug plasma concentrations of decitabine and genistein. | Plasma drug levels will be used to obtain preliminary PK profile. Up to 11 blood samples to be obtained from each enrolled patient, over several cycles. | Up to 6 , 28 day treatment cycles | No |
Secondary | Preliminary clinical efficacy assessment | Preliminary efficacy of the investigational regimen will include the assessment of Overall Response Rate ( ORR) and Progression Free Survival(PFS) | Up to 6, 28 day treatment cycles | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |